当前位置: X-MOL 学术Mol. Ther. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RNA base editing therapy cures hearing loss induced by OTOF gene mutation
Molecular Therapy ( IF 12.1 ) Pub Date : 2023-11-02 , DOI: 10.1016/j.ymthe.2023.10.019
Yuanyuan Xue 1 , Yong Tao 2 , Xing Wang 3 , Xueling Wang 2 , Yilai Shu 4 , Yuanhua Liu 5 , Wen Kang 2 , Sifan Chen 3 , Zhenzhe Cheng 2 , Boou Yan 3 , Yanwei Xie 3 , Lanting Bi 3 , Haitao Jia 3 , Jinhui Li 3 , Qingquan Xiao 3 , Liying Chen 3 , Xuan Yao 3 , Linyu Shi 3 , Hui Yang 6 , Hao Wu 2
Affiliation  

Otoferlin (OTOF) gene mutations represent the primary cause of hearing impairment and deafness in auditory neuropathy. The c.2485C>T (p. Q829X) mutation variant is responsible for approximately 3% of recessive prelingual deafness cases within the Spanish population. Previous studies have used two recombinant AAV vectors to overexpress OTOF, albeit with limited efficacy. In this study, we introduce an enhanced mini-dCas13X RNA base editor (emxABE) delivered via an AAV9 variant, achieving nearly 100% transfection efficiency in inner hair cells. This approach is aimed at treating OTOFQ829X, resulting in an approximately 80% adenosine-to-inosine conversion efficiency in humanized OtofQ829X/Q829X mice. Following a single scala media injection of emxABE targeting OTOFQ829X (emxABE-T) administered during the postnatal day 0–3 period in OtofQ829X/Q829X mice, we observed OTOF expression restoration in nearly 100% of inner hair cells. Moreover, auditory function was significantly improved, reaching similar levels as in wild-type mice. This enhancement persisted for at least 7 months. We also investigated P5–P7 and P30 OtofQ829X/Q829X mice, achieving auditory function restoration through round window injection of emxABE-T. These findings not only highlight an effective therapeutic strategy for potentially addressing OTOFQ829X-induced hearing loss but also underscore emxABE as a versatile toolkit for treating other monogenic diseases characterized by premature termination codons.



中文翻译:


RNA 碱基编辑疗法治愈 OTOF 基因突变引起的听力损失



耳铁蛋白 (OTOF) 基因突变是听觉神经病变中听力障碍和耳聋的主要原因。c.2485C>T (p. Q829X) 突变变体导致西班牙人群中约 3% 的隐性舌前耳聋病例。以前的研究使用两种重组 AAV 载体过表达 OTOF,尽管疗效有限。在这项研究中,我们引入了一种通过 AAV9 变体递送的增强型 mini-dCas13X RNA 碱基编辑器 (emxABE),在内毛细胞中实现了近 100% 的转染效率。这种方法旨在治疗 OTOFQ829X,导致人源化 OtofQ829X/Q829X 小鼠的腺苷到肌苷转化效率约为 80%。在 OtofQ829X/Q829X 小鼠出生后第 0-3 天期间注射靶向 OTOFQ829X (emxABE-T) 的单次标量培养基注射后,我们观察到近 100% 的内毛细胞中 OTOF 表达恢复。此外,听觉功能得到显著改善,达到与野生型小鼠相似的水平。这种增强持续了至少 7 个月。我们还研究了 P5-P7 和 P30 OtofQ829X/Q829X 小鼠,通过圆窗注射 emxABE-T 实现听觉功能恢复。这些发现不仅强调了一种可能解决 OTOFQ829X 诱导的听力损失的有效治疗策略,而且还强调了 emxABE 是治疗其他以过早终止密码子为特征的单基因疾病的多功能工具包。

更新日期:2023-11-02
down
wechat
bug